Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CORVUS PHARMACEUTICALS, INC.

(CRVS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Corvus Pharmaceuticals : Cantor Fitzgerald Adjusts Price Target on Corvus Pharmaceuticals to $5 From $10, Maintains Overweight Rating

08/03/2021 | 09:51am EDT


ę MT Newswires 2021
All news about CORVUS PHARMACEUTICALS, INC.
10/27Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval fo..
AQ
09/22Health Care Stocks Follow Market Higher Wednesday
MT
09/22Health Care Stocks Edge Higher Premarket Wednesday
MT
09/22CORVUS PHARMACEUTICALS : Reports Results of Phase 3 Trial of Mupadolimab; Shares Fall Pre-..
MT
09/22Corvus Pharmaceuticals Provides Updates on Mupadolimab (Anti-CD73) Programs in Oncology..
GL
09/22Corvus Pharmaceuticals Provides Updates on Mupadolimab
CI
09/17Top Premarket Gainers
MT
09/07Corvus Pharmaceuticals Announces Participation in Upcoming Investor Conferences
GL
08/17CORVUS PHARMACEUTICALS : Announces IND Acceptance for Phase 1/1b Clinical Trial of CPI-1 i..
AQ
08/17CORVUS PHARMACEUTICALS' : Chinese Partner Gets Regulatory Nod to Conduct Early Stage Study..
MT
More news
Analyst Recommendations on CORVUS PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -40,1 M - -
Net Debt 2021 - - -
P/E ratio 2021 -4,75x
Yield 2021 -
Capitalization 193 M 193 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 5,67x
Nbr of Employees 42
Free-Float 88,4%
Chart CORVUS PHARMACEUTICALS, INC.
Duration : Period :
Corvus Pharmaceuticals, Inc. Technical Analysis Chart | CRVS | US2210151005 | MarketScreener
Technical analysis trends CORVUS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 4,56 $
Average target price 5,13 $
Spread / Average Target 12,4%
EPS Revisions
Managers and Directors
Richard A. Miller Chairman, President & Chief Executive Officer
Leiv Lea Chief Financial Officer
Suresh Mahabhashyam Vice President-Clinical Development
Peter A. Thompson Independent Director
Elisha P. Gould Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CORVUS PHARMACEUTICALS, INC.28.09%193
MODERNA, INC.226.29%137 595
LONZA GROUP AG32.74%61 065
IQVIA HOLDINGS INC.41.93%48 579
SEAGEN INC.-0.30%31 768
CELLTRION, INC.-39.00%25 528